Cargando…
Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm that, if not treated, will progress into blast crisis (BC) of either myeloid or B lymphoid phenotype. The BCR-ABL1 fusion gene, encoding a constitutively active tyrosine kinase, is thought to be sufficient to cause chronic phase (CP) CM...
Autores principales: | Askmyr, M, Ågerstam, H, Lilljebjörn, H, Hansen, N, Karlsson, C, von Palffy, S, Landberg, N, Högberg, C, Lassen, C, Rissler, M, Richter, J, Ehinger, M, Järås, M, Fioretos, T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315895/ https://www.ncbi.nlm.nih.gov/pubmed/25501026 http://dx.doi.org/10.1038/bcj.2014.89 |
Ejemplares similares
-
Transgenic expression of human cytokines in immunodeficient mice does not facilitate myeloid expansion of BCR-ABL1 transduced human cord blood cells
por: Askmyr, Maria, et al.
Publicado: (2017) -
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
por: Landberg, Niklas, et al.
Publicado: (2018) -
SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like
disease and for normal hematopoietic stem cell function
por: Hansen, N, et al.
Publicado: (2013) -
A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells
por: von Palffy, Sofia, et al.
Publicado: (2020) -
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
por: von Palffy, Sofia, et al.
Publicado: (2022)